Alligator Bioscience AB: Correction regarding MAR marking
The press release as of October 21, 2021 regarding the Interim report January – September 2021 incorrectly contained a so-called MAR marking. This was not the company's intention, as the information is not to be regarded as inside information. For further information, please contact: Julie Silber, Investor RelationsPhone: +46 46-540 82 23E-mail: jur@alligatorbioscience.com About Alligator Bioscience Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. The pipeline includes two clinical assets: mitazalimab,